PURPOSE: To evaluate the postradiotherapy 5-year cancer-specific (CSS), clinical progression-free (cPFS), and overall ( @entity3012 ) survival rates in @entity1 with pN0 @entity263 ( @entity263 ). METHODS: Between 1989 and 1996, 203 consecutive pN0 M0 @entity263 @entity1 (T1-2, 66; T3-4, 137) received conformal prostatic four-field radiotherapy (median target dose 66 Gy). Any hormone manipulation was delayed until clinical progression (growth of the @entity5 or development of distant metastases). RESULTS: After a median observation time of 87 months (range 11-156), 99 @entity1 had relapsed clinically and 70 @entity1 were dead, 37 of them as a result of @entity263 . Five-year CSS, cPFS, and @entity3012 rates were, respectively, 90% (95% CI 86-94%), 64% (95% CI 57-71%), and 82% (95% CI 77-87%), with no difference of @entity3012 compared with age-matched males from the general population. Gleason score (< or =7A vs. > or =7B) and the T category predicted cPFS, whereas CSS was associated with Gleason score only. Preradiotherapy PSA failed to predict survival. @entity1 with T1-2 Gleason score < or =7A had a 97% 5-year CCS, as compared with 89% for all other @entity1 . A median of eight lymph nodes (range 0-29) were described in the specimens from pelvic lymphadenectomy (LA). CONCLUSION: Despite still preliminary observations, our 5-year results challenge the use of combined hormone radiotherapy in @entity1 who are proven to be pN0 by preradiotherapy LA; in particular, in @entity1 with T1-2/Gleason score < or =7A, whereas the survival in all other @entity1 with pN0 @entity263 may be improved by adjuvant @entity342 deprivation.

Definitive radiotherapy of XXXX : the possible role of staging lymphadenectomy.

@entity1 :: ('9606', 'Species') :: ['Patients', 'patients'] @entity263 :: ('MESH:D011471', 'Disease') :: ['M0 prostate cancer', 'PC', 'prostate cancer'] @entity3012 :: ('MESH:C567932', 'Disease') :: ['OS'] @entity5 :: ('MESH:D009369', 'Disease') :: ['primary tumor'] @entity342 :: ('CHEBI:50113', 'Chemical') :: ['androgen']
@entity263 :: (MESH:D011471,Disease) :: ['prostate cancer']
